Editorial
Tumor treating fields—effective, but at what cost?
Abstract
Each year in the United States, 21,500 adults are diagnosed with a neuroepithelial brain tumor. Most are an aggressive malignant neoplasm called glioblastoma multiforme
(GBM) (1). Despite extensive resection, combined chemoradiation therapy, salvage chemotherapy with alkylating agents and monoclonal antibodies targeting vascular endothelial derived growth factor (VEGF), the median survival after a diagnosis of GBM is 14.6 months. Only 4.3% of patients live five years or more (1).
(GBM) (1). Despite extensive resection, combined chemoradiation therapy, salvage chemotherapy with alkylating agents and monoclonal antibodies targeting vascular endothelial derived growth factor (VEGF), the median survival after a diagnosis of GBM is 14.6 months. Only 4.3% of patients live five years or more (1).
